Patients were followed for a median of 36 months, and close to half were followed for at least four years, as updated by Dr. Katz during his presentation. Actuarial five-year disease-free survival was 95 percent for low-risk patients, 90 percent for intermediate-risk patients and 80 percent for high-risk patients.....now are they a player or what?
i'm one of those still disease free. But I know that there is more in the Stock Market than quality product, even in medicine, especially when competitors are quick to copy. I own some stock..but my oncologist source thinks Accuray has a good machine, but so does the competition and that the business end of aray is weak. Again, please comment.